PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity - Archive ouverte HAL Access content directly
Journal Articles Cells Year : 2022

PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity

(1) , (2, 3) , (1)
1
2
3

Abstract

Metabolic rewiring and defective immune responses are considered to be the main driving forces sustaining cell growth and oncogenesis in many cancers. The atypical enzyme, proprotein convertase subtilisin/kexin type 9 (PCSK9), is produced by the liver in large amounts and plays a major role in lipid metabolism via the control of the low density lipoprotein receptor (LDLR) and other cell surface receptors. In this context, many clinical studies have clearly demonstrated the high efficacy of PCSK9 inhibitors in treating hyperlipidemia and cardiovascular diseases. Recent data implicated PCSK9 in the degradation of major histocompatibility complex I (MHC-I) receptors and the immune system as well as in other physiological activities. This review highlights the complex crosstalk between PCSK9, lipid metabolism and immunosuppression and underlines the latest advances in understanding the involvement of this convertase in other critical functions. We present a comprehensive assessment of the different strategies targeting PCSK9 and show how these approaches could be extended to future therapeutic options to treat cancers with a main focus on the liver.
Fichier principal
Vignette du fichier
cells-11-04132.pdf (1.51 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

inserm-03920559 , version 1 (03-01-2023)

Identifiers

Cite

Malak Alannan, Nabil Seidah, Aksam Merched. PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity. Cells, 2022, 11 (24), pp.4132. ⟨10.3390/cells11244132⟩. ⟨inserm-03920559⟩

Collections

INSERM
0 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More